Clinical Intelligence

Common canine virus may lead to new vaccines for deadly human diseases

Friday, November 30, 2012 11:21 AM

Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for the next great breakthrough in human vaccine development.

More... »

FDA approves Cometriq to treat rare type of thyroid cancer

Thursday, November 29, 2012 08:00 AM

The FDA has approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body.

More... »

Almirall’s Constella approved in Europe for IBS-C

Wednesday, November 28, 2012 12:20 PM

The European Commission has granted marketing authorization to Almirall’s Constella (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.

More... »

Savara's AeroVanc granted Orphan Drug status for MRSA lung infection in CF

Tuesday, November 20, 2012 11:23 AM

The FDA has granted orphan drug status to Savara Pharmaceuticals’ AeroVanc (vancomycin hydrochloride inhalation powder) for the treatment of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis (CF).

More... »

Abbott announces phase III Hep C program details

Friday, November 16, 2012 02:25 PM

Abbott Laboratories, a global healthcare company, has released details on its phase III hepatitis C registration program following promising results from its phase IIb clinical trial, known as Aviator.

More... »

TissueGene completes enrollment in phase II TG-C study of in knee osteoarthritis

Thursday, November 15, 2012 08:00 AM

TissueGene, is a Rockville, Md.-based biopharmaceutical company focused on developing novel regenerative therapies, has completed patient enrollment for a U.S. phase II clinical trial of TG-C in patients with severe osteoarthritis of the knee. 

More... »

Protein predicts diabetes risk many years in advance

Wednesday, November 14, 2012 03:05 PM

When a patient is diagnosed with type 2 diabetes, the disease has usually already progressed over several years and damage to areas such as blood vessels and eyes has already taken place. To find a test that indicates who is at risk at an early stage would be valuable, as it would enable preventive treatment to be put in place.

More... »

FDA grants Soligenix Fast Track designation for SGX203 for Crohn's disease

Friday, November 9, 2012 12:44 PM

Soligenix, a development stage biopharmaceutical company based in Princeton, N.J., announced that its drug SGX203, for the treatment of mild-to-moderate pediatric Crohn's disease, has received Fast Track designation from the FDA.

More... »

AcelRx doses first patients in ARX-04 phase II study in pain

Wednesday, November 7, 2012 03:09 PM

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on the treatment of acute and breakthrough pain, has dosed the first subjects in a phase II, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate. 

More... »

FDA grants Bayer’s Stivarga NDA priority review

Thursday, November 1, 2012 11:49 AM

Bayer HealthCare and Onyx Pharmaceuticals, a biopharmaceutical company based in South San Francisco, announced today that the FDA has granted priority review to the New Drug Application (NDA) for Stivarga (regorafenib) tablets.

More... »